The Truth About PCOS, PMOS & GLP-1s :: Dr. Kamilia Smith [Ep 575]

The podcast features Dr. Kamilia Smith discussing the evolving understanding of polycystic ovarian syndrome (PCOS) now being renamed to polyendocrine metabolic ovarian syndrome (PMOS). Historically viewed as primarily a reproductive disorder, current insights suggest that PCOS/PMOS is more about systemic metabolic issues reflected by ovarian symptoms. Dr. Smith explains how this reclassification aims to shift the focus from ovarian dysfunction as the root cause toward understanding it as a messenger indicating deeper metabolic, hormonal, and inflammatory conditions. This change aims to promote early intervention and holistic treatment targeting metabolic health rather than just ovarian symptoms.

Dr. Smith provides a detailed explanation of PCOS's traditional diagnosis based on ultrasound findings and hormone levels, emphasizing that it is primarily a clinical diagnosis based on symptoms such as irregular cycles, hyperandrogenism (excess hair, acne), and weight issues. She critiques past overdiagnosis driven by ultrasound appearances, which do not necessarily confirm the syndrome, and highlights the importance of assessing hormone levels and physical signs—such as dark terminal hair and weight distribution. She stresses the complexity of diagnosing and managing the condition, especially in young girls where the hormonal axis may still be maturing, advocating for careful, comprehensive evaluation rather than early labeling.

The episode discusses how treatment traditionally focused on suppressing ovarian activity with birth control pills, mainly to regulate symptoms and protect the uterine lining. However, Dr. Smith emphasizes the importance of addressing underlying metabolic issues like insulin resistance, inflammation, and visceral fat accumulation. She advocates for lifestyle changes such as increased movement, diet improvements, and weight management as foundational strategies. Additionally, the use of medications like GLP-1 receptor agonists (e.g., Ozempic) was explored, stressing the importance of medical guidance and real health benefits—such as reduction in migraines and depression, and better metabolic health—beyond just weight loss.

Dr. Smith shares her insights on the promising use of GLP-1 medications in treating women with PMOS, especially in terms of improving insulin sensitivity, body composition, and mitigating long-term health risks like cardiovascular disease. She clarifies that while off-label use of these drugs can be beneficial for metabolic health, formal FDA approval is required for official treatment. The conversation also touches on how these medications can positively impact mental health, sexual function, and symptoms like migraines and depression—highlighting a compassionate, whole-woman approach to health management.

A significant part of the discussion addresses how moms can support their daughters in navigating hormonal health from an early age without over-pathologizing or causing fear. Dr. Smith advises allowing children to be children, promoting healthy relationships with food, movement, and body image, and avoiding early labels and diagnosis. She emphasizes that irregular cycles in young girls are often normal due to ongoing hormonal development, and that careful, holistic observation is key. The importance of open, age-appropriate conversations about body, health, and self-love are stressed to foster resilience and healthy attitudes.

The episode underscores the importance of understanding metabolic health as central to women's reproductive and overall well-being. The rebranding from PCOS to PMOS is a step toward holistic, upstream treatment rather than only symptom management. Lifestyle, movement, and medical therapies like GLP-1s are powerful tools. Dr. Smith encourages women and moms to seek comprehensive care, avoid early overdiagnosis, and focus on long-term health and empowerment through education, support, and gentle intervention.